Dr Helen Yang to Join Venture Panel at Georgia MedTech Innovation Summit 2024
Nikolai "Nik" Nikitin, MD, PhD
President and Founder at Clinical Accelerator
The Georgia MedTech Innovation Summit is pleased to announce that Dr Helen Yang will be joining the Venture Panel “Funding early clinical development of innovative cardiovascular devices” on Day 1 – September 20.
About Dr. Helen Yang:
Dr. Helen Yang holds a Ph.D. in Biomedical Engineering and currently serves as the Senior Vice President and Chief Investment Officer of Fosun MedTech, the MedTech division of Fosun Pharma (600196.SH, 02196.HK).
Dr. Helen Yang has extensive experience in research and development, technology introduction, investment, and integrated operations within the field of MedTech. As a core member, she has successfully commercialized several innovative MedTech projects in China through an early incubation/technology introduction + deep operation model, including Broncus Medical (02216.HK), JediCare, and others. She has also played a leading role in multiple deals introducing global innovative MedTech projects into China through joint-venture partnerships, such as the "Fosun-Insightec" joint venture between Fosun Pharma and Insightec Ltd. Dr. Helen Yang has also led equity investments globally in a number of innovative MedTech projects, including Sonendo (NYSE: SONX), Human Xtensions (TASE: HUMX), TruTag Technologies, and ZuriMED Technologies AG.?
About the Georgia MedTech Innovation Summit:
The Georgia MedTech Innovation Summit aims to unite a dynamic community of companies, KOLs, physicians, investors, and strategists within the medtech sector who are interested in or are currently conducting early stage studies O-US. The event offers a platform for sharing knowledge, networking, and fostering collaboration in the development of groundbreaking medical technologies. Being a hybrid event, the summit will provide educational discussions with KOLs on technology advancements and strategically relevant talks for medtech companies and investors on efficient and successful execution of studies with an extra focus on regulatory and EFS (Early Feasibility Studies).